HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kristeller, J. L. Articles by Stahl, R. F. Search for Related Content PubMed PubMed Citation Articles by Kristeller, J. L. Articles by Stahl, R. F.

JUDITH LYN KRISTELLER, PHARM.D., BCPS, is Assistant Professor, Department of Pharmacy Practice; and HALEY PAPPS, PHARM.D., is a recent graduate of Wilkes University, Wilkes-Barre, PA. RUSSELL F. STAHL, M.D., FACS, is Chief of Cardiothoracic Surgery, Community Medical Center, Scranton, PA.

Address correspondence to Dr. Kristeller at the Department of Pharmacy Practice, Wilkes University, 84 West South Street, SLC 336, Wilkes-Barre, PA 18766 (judith.kristeller{at}wilkes.edu).

Purpose. The relationship between the perioperative use of nesiritide and the development of postoperative renal insufficiency in open-heart surgery (OHS) patients is discussed. Summary. Postoperative renal dysfunction occurs in about 8% of patients who undergo elective coronary bypass surgery. The worsening of renal function is associated with increased length of stay and mortality. Nesiritide, a vasodilator, improves the hemodynamic profile and symptoms in patients with acute decompensated heart failure (ADHF). Because patients undergoing OHS have physiological characteristics similar to ADHF, it is theorized that nesiritide could preserve renal function by opposing the neurohormonal response to OHS. However, there has been recent attention on the potential nephrotoxic effects of nesiritide in patients with heart failure, although the association between these effects and nesiritide is unclear. There is little clinical evidence supporting the use of nesiritide in OHS patients. Three small studies have demonstrated beneficial hemodynamic effects of nesiritide; one prospective, controlled trial evaluated the effect of nesiritide on renal function and found no significant difference between nesiritide and placebo; and two small studies demonstrated renal-protective effects of nesiritide in cardiac surgery patients. Conclusion. Evidence of the clinical benefit of nesiritide on renal function in patients undergoing OHS is controversial. A prospective, controlled trial is needed to determine the effect of nesiritide on renal function. Regardless, it is recommended that patients at risk for worsening renal function after OHS should be identified and targeted for interventions aimed at preserving renal function and improving outcomes. Index terms: Cardiac drugs; Heart failure; Hemodynamics; Kidney failure; Nesiritide; Surgery; Toxicity

 

This article has been cited by other articles:

				A. Dunn and S. Sachak Nesiritide and renal function after cardiac surgery Am. J. Health Syst. Pharm., August 1, 2007; 64(15): 1582 - 1584. [Full Text] [PDF]